These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 26577299)

  • 1. Targeting Mutant AKT in Cancer.
    Cancer Discov; 2016 Jan; 6(1):OF7. PubMed ID: 26577299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AKT Inhibition in Solid Tumors With AKT1 Mutations.
    Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
    J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
    Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
    Weller M; Roth P; Sahm F; Burghardt I; Schuknecht B; Rushing EJ; Regli L; Lindemann JP; von Deimling A
    J Natl Cancer Inst; 2017 Mar; 109(3):1-4. PubMed ID: 28376212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.
    Tamura K; Hashimoto J; Tanabe Y; Kodaira M; Yonemori K; Seto T; Hirai F; Arita S; Toyokawa G; Chen L; Yamamoto H; Kawata T; Lindemann J; Esaki T
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):787-95. PubMed ID: 26931343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKT1
    John P; Waldt N; Liebich J; Kesseler C; Schnabel S; Angenstein F; Sandalcioglu IE; Scherlach C; Sahm F; Kirches E; Mawrin C
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12780. PubMed ID: 34837233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
    Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
    Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-treatment of Salinomycin Sensitizes AZD5363-treated Cancer Cells Through Increased Apoptosis.
    Choi AR; Jung MJ; Kim JH; Yoon S
    Anticancer Res; 2015 Sep; 35(9):4741-7. PubMed ID: 26254364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment.
    Searle EJ; Telfer BA; Mukherjee D; Forster DM; Davies BR; Williams KJ; Stratford IJ; Illidge TM
    EMBO Mol Med; 2017 Dec; 9(12):1646-1659. PubMed ID: 29084756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT1(E17K) in human solid tumours.
    Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
    Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.
    de Bruin EC; Whiteley JL; Corcoran C; Kirk PM; Fox JC; Armisen J; Lindemann JPO; Schiavon G; Ambrose HJ; Kohlmann A
    PLoS One; 2017; 12(5):e0175779. PubMed ID: 28472036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
    Lamoureux F; Thomas C; Crafter C; Kumano M; Zhang F; Davies BR; Gleave ME; Zoubeidi A
    Clin Cancer Res; 2013 Feb; 19(4):833-44. PubMed ID: 23258740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363.
    Yates JW; Dudley P; Cheng J; D'Cruz C; Davies BR
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):343-56. PubMed ID: 26092323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
    Addie M; Ballard P; Buttar D; Crafter C; Currie G; Davies BR; Debreczeni J; Dry H; Dudley P; Greenwood R; Johnson PD; Kettle JG; Lane C; Lamont G; Leach A; Luke RW; Morris J; Ogilvie D; Page K; Pass M; Pearson S; Ruston L
    J Med Chem; 2013 Mar; 56(5):2059-73. PubMed ID: 23394218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
    Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
    Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gain of function mutation in AKT1 increases hexokinase 2 and diminishes oxidative stress in meningioma.
    Singh S; Lathoria K; Umdor SB; Singh J; Suri V; Sen E
    Cytokine; 2024 Apr; 176():156535. PubMed ID: 38325141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRK Inhibitor Shows Early Promise.
    Cancer Discov; 2016 Jan; 6(1):OF4. PubMed ID: 26603524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
    Landgraf KE; Pilling C; Falke JJ
    Biochemistry; 2008 Nov; 47(47):12260-9. PubMed ID: 18954143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer.
    Bose S; Kalinsky K
    Clin Breast Cancer; 2021 Jun; 21(3):e150-e153. PubMed ID: 33177006
    [No Abstract]   [Full Text] [Related]  

  • 20. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
    Meric-Bernstam F; Brusco L; Shaw K; Horombe C; Kopetz S; Davies MA; Routbort M; Piha-Paul SA; Janku F; Ueno N; Hong D; De Groot J; Ravi V; Li Y; Luthra R; Patel K; Broaddus R; Mendelsohn J; Mills GB
    J Clin Oncol; 2015 Sep; 33(25):2753-62. PubMed ID: 26014291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.